Sanofi moved to license ADEL Inc.’s tau‑targeting antibody ADEL‑Y01, paying $80 million up front with the deal carrying potential total payments up to $1.04 billion. ADEL‑Y01 is a humanized monoclonal antibody currently in a U.S. phase I study for Alzheimer’s disease; the agreement gives Sanofi global rights to the asset and related backups. Sanofi said the candidate addresses tau pathology and could complement its existing neurology programs. ADEL will be eligible for milestone and tiered royalty payments and retains no global commercialization rights under the deal. The transaction reflects large pharma’s continued willingness to buy targeted neuroscience wagers with clinical proof points. The pact accelerates ADEL’s cash runway and derisks early‑stage development for the antibody while shifting late‑stage costs and commercialization planning to Sanofi. The market will watch Sanofi’s planned development program and biomarker strategy, including any plans for accelerated pathways or enriched cohorts.